
Bicara Therapeutics advances cancer drug trial with strong cash to fund operations through 2029
Bicara Therapeutics is progressing its Phase 3 trial of ficerafusp alfa for head and neck cancer, expecting interim results by mid-2027 that could support accelerated approval. The company holds nearly $500 million in cash and securities, funding ope...

